Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human GEN3017 trial in relapsed or refractory Hodgkin lymphoma or non-Hodgkin lymphoma
NL-OMON59035Phase 2Completed
- Sponsor
- Genmab
- Start
- Dec 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of gen3017 in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), classical Hodgkin lymphoma (cHL) and 1 more (2 arms), sponsored by Genmab. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and 1 more. Started Dec 2023; status: completed.
02
Drugs
gen3017
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)classical Hodgkin lymphoma (cHL)T-cell lymphoma
Beyond the preview
Go deeper on NL-OMON59035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59035.